Search Results for: Avandia

Featured Stories
Indiana Woman Alleges Serious Injuries From Transvaginal Mesh Products

Indiana Woman Alleges Serious Injuries From Transvaginal Mesh Products

Parker Waichman LLP, a national law firm, just filed a lawsuit on behalf of a woman who suffered injuries after receiving transvaginal mesh implants. The lawsuit suit alleges that the transvaginal mesh created an unreasonable risk and directly caused her injuries.

Read More

Canadian Study Confirms Actos Bladder Cancer Risk

Canadian Study Confirms Actos Bladder Cancer Risk

A new study conducted by Canadian researchers has found that users of the type 2 diabetes drug, Actos (pioglitazone), may face a higher risk of developing bladder cancer than first thought. The study, published in the British Medical Journal, found that taking Actos for two years doubles the likelihood ...

Read More

First Bard Avaulta Transvaginal Mesh Lawsuit Scheduled for February Trial in MDL

First Bard Avaulta Transvaginal Mesh Lawsuit Scheduled for February Trial in MDL

The first test trials in the federal C.R. Bard Avaulta transvaginal mesh litigation will most likely start next year, according to a report from Bloomberg News. About 600 lawsuits involving Bard Avaulta transvaginal mesh products are currently pending in the multidistrict litigation underway Charleston, West Virginia. U.S. District Judge Joseph ...

Read More

Another Metal-on-Metal Hip Replacement Lawsuit Filed in DePuy ASR Hip Implant Litigation

Another Metal-on-Metal Hip Replacement Lawsuit Filed in DePuy ASR Hip Implant Litigation

A vital food safety program was saved from budget cuts this week, enabling the country’s largest—although considered by experts to be far too small—produce-safety testing program to continue.

Read More

FDA Metal-On-Metal Hip Replacement Investigation Is Flawed, Researchers Say

FDA Metal-On-Metal Hip Replacement Investigation Is Flawed, Researchers Say

The U.S. Food & Drug Administration’s (FDA) metal-on-metal hip replacement investigation is flawed, according to researchers.

Read More

New York Man Claims Biomet Metal-on-Metal Hip Implant Caused Pain, Disability

New York Man Claims Biomet Metal-on-Metal Hip Implant Caused Pain, Disability

A New York man claims his metal-on-metal hip implant was defective and required replacement within a year of receiving it. This has left him facing a lifetime of pain, disability, and rising medical costs.

Read More

Actos Whistleblower Lawsuit Questions Avandia Researcher’s Financial Ties to Takeda

Actos Whistleblower Lawsuit Questions Avandia Researcher's Financial Ties to Takeda

A prominent researcher has been implicated in an alleged cover-up of Actos side effects, according to a report from TheHeart.org. An Actos whistleblower lawsuit unsealed earlier this year has alleged financial connections between the Cleveland Clinic’s Dr Steven Nissen and the maker of Actos “should be considered when analyzing Actos’s ...

Read More

West Virginia Man Claims Metal-on-Metal DePuy Pinnacle Hip Replacement Led to Pain, Elevated Cobalt Levels

West Virginia Man Claims Metal-on-Metal DePuy Pinnacle Hip Replacement Led to Pain, Elevated Cobalt Levels

A West Virginia man fitted with a metal-on-metal version of DePuy Orthopaedics’ Pinnacle Hip Implant System has filed suit against the company and its parent, Johnson & Johnson, alleging the device caused him to suffer pain and elevated cobalt levels. The Plaintiff is being represented by the national law ...

Read More

Medtronic Infuse Lawsuit Alleges Off-Label Use Cause Painful Complications

Medtronic Infuse Lawsuit Alleges Off-Label Use Cause Painful Complications

A man in Louisiana has filed suit against Medtronic Inc. over injuries allegedly cause by off-label use of its Infuse Bone Graft product. The plaintiff, who received Infuse during transforaminal spinal lumbar fusion surgery, claims that the bone growth protein caused unwanted bone growth along his spine, worsening the back ...

Read More

Majority of Metal-on-Metal Hip Implant Failures Occur within Two Years, Study Finds

Majority of Metal-on-Metal Hip Implant Failures Occur within Two Years, Study Finds

A newly published metal-on-metal hip replacement study is reporting that the majority of failures occur early, within two years of surgery. The study, published in the journal Orthopedics, is just the latest to indicate that close follow-up of metal-on-metal hip implant patients is warranted.

Read More

FDA Reviews Heart Failure Risks Associated with Diabetes Drugs Onglyza and Kombiglyze

onglyza-and-kombiiglyze-cardiac-risks

In a Drug Safety Communication issued Tuesday, the U.S. Food and Drug Administration (FDA) said that it has requested clinical trial data to analyze the association between heart failure and saxagliptin, a Type 2 diabetes drug marketed as Onglyza and … Continue reading

Posted in Legal News |

Despite Increasing Injury Reports, Mounting Lawsuits, and Growing Data, FDA, EMA Will Not Confirm Increased Pancreatic Side Effects with Incretin Drugs

increting_drugs_side_effects

The U.S. Food and Drug Administration (FDA) agrees with the European Medicines Agency (EMA) that prevailing data concerning Type 2 diabetes medications in the class known as glucagonlike peptide-1 (GLP-1)-based diabetes therapies, do not confirm increased pancreatic side effect risks, … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

Glaxo Agrees to $229 Million Avandia Settlement with Eight States

glaxo_avandia_settlement

In response to lawsuits brought by eight U.S. states, drug maker, GlaxoSmithKline, has agreed to pay hundreds of millions of dollars to settle actions over diabetes medication, Avandia (rosiglitazone). The drug maker announced it would pay $229 million and, in … Continue reading

Posted in Avandia, Pharmaceuticals |

Texas Man Files Lawsuit Alleging Actos Caused His Bladder Cancer

texas_actos_bladder_cancer_lawsuit

A Texas man has filed a lawsuit in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-02229) alleging that the diabetes drug Actos is to blame for his bladder cancer. This case is one of thousands … Continue reading

Posted in Actos, Health Concerns, Pharmaceuticals |

Drug Maker, Roche, Ceases New Type 2 Diabetes Drug Testing Over Safety Risks

roche_diabetes_drugs

Drug maker, Roche, just announced it has stopped development of a diabetes drug that is in the same class as the Type 2 diabetes drugs Actos and Avandia. The move, according to The New York Times, could raise safety concerns … Continue reading

Posted in Actos, Avandia, Pharmaceuticals |

Diabetes Drug Fails to Cut Heart Risks, Clinical Trial Shows

onglyza_heart_health_ineffective

In a large clinical trial, Onglyza (saxagliptin), a Type 2 diabetes medication, failed to reduce the risk of heart attacks and related disease compared with a placebo. But the drug, co-marketed by Bristol-Myers Squibb and AstraZeneca, did not increase cardiovascular … Continue reading

Posted in Avandia, Health Concerns, Pharmaceuticals |

Type 2 Diabetes Medication Risks Examined in Journal Review

type2_diabetes_drugs

Incretin mimetics, a class of Type 2 diabetes drugs, are sparking debate and renewing concerns about health risks, especially to the pancreas. In fact, a piece published in the journal BMJ, states that the drugs, which include Byetta and Januvia, … Continue reading

Posted in Byetta Cancer, Pharmaceuticals |

New Lawsuit Alleges Actos Caused Arizona Man’s Bladder Cancer

Arizona_Actos_Bladder_Cancer

An Arizona man who took the diabetes drug Actos (pioglitazone) for several years has filed a lawsuit alleging that the drug caused his bladder cancer. The lawsuit further alleges that Takeda Pharmaceuticals, the drug’s manufacturer, was aware of the risk … Continue reading

Posted in Actos, Health Concerns, Pharmaceuticals |

FDA Recommends Easing Avandia Restrictions

FDA_Avandia_Restrictions

A vote at the conclusion of a two-day meeting of United States health advisors ended with a recommendation to ease current market restrictions on Type 2 diabetes drug, Avandia, which is marketed by GlaxoSmithKline. The U.S. Food and Drug Administration … Continue reading

Posted in Avandia, Legal News, Pharmaceuticals |

FDA Reconsidering its Stance on Avandia

FDA-Avandia-Restrictions

In an unprecedented move, the U.S. Food and Drug Administration is reopening the matter involving Type 2 diabetes drug, Avandia, which is marketed by GlaxoSmithKline. Avandia belongs to a class of diabetes drugs called thiazolidinediones that lower blood sugar by … Continue reading

Posted in Avandia, Pharmaceuticals |